Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

September 11th, 2015: Aurgalys releases an analyst report on Diaxonhit [Alternext:ALEHT]

septembre 11, 2015

Paris-Evry, France, September 11th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Diaxonhit

« Since 2014, Diaxonhit has been participating in the HIV consortium PROTHEVIH, which aims at developing innovative drugs and diagnostic tests to improve the management of HIV patients. After project leader Innavirvax published promising results on the VAC-3S therapeutic vaccine, Diaxonhit announced it will have a first prototype of an HIV prognosis test in H1-2016 (DIAG-3S). The company needs to demonstrate that the naturally-secreted antibodies against the 3S peptide (highly conserved on the HIV virus) can be used as an early marker of prognosis in HIV-infected patients. After validating the test, Diaxonhit could market DIAG-3S as early as 2018. Following this announcement, we adjusted our target price to €1.62/share. »

You can download analyst report (in English) on the following link:

Comments are closed.